To conclude, our results showed that both NDRG1 overexpression and treatment with DpdtC caused significant inhibitory effect on HER2/EGFR heterodimer formation and ERK1/2 activation, which may be a novel mechanism involved in the potent anti-tumor activity of DpdtC. The gene discussed is NDRG1; the disease is neoplasm.